From: Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer
Variable
Odds Ratio (95%) CI
p value
Tumor Stage (III-IV)
1.983 (0.671–5.994)
0.215
Lymph Node Involvement (yes)
1.601 (0.535–4.672)
0.393
Tumor Size (≥2 cm)
3.153 (1.363–7.636)
0.009